Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?
Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9.
Biogen Inc. (BIIB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Sivik Global Healthcare Krishen Sud | 15,000 | $3,388,200 | 1.94% | |
| 2. | Motley Fool Asset Management Bryan Hinmon | 2,649 | $598,356 | -12% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $195.04 | 3 | $585.11 | 19,611 | 2026-02-12 | Filing | |
| $122.72 | 1,235 | $151,559.20 | 27,842 | 2025-05-02 | Filing | |
| $222.54 | 455 | $101,255.70 | 20,629 | 2024-02-15 | Filing | |
| $267.00 | 898 | $239,766.00 | 2,943 | 2021-02-09 | Filing | |
| $241.31 | 3,100 | $748,046.74 | 34,810 | 2020-11-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $200.96 | 593 | $119,169.28 | 2,689 | 2026-08-04 | Filing | |
| $203.34 | 593 | $120,580.62 | 3,282 | 2026-08-03 | Filing | |
| $199.83 | 2,660 | $531,547.80 | 8,043 | 2026-02-09 | Filing | |
| $179.30 | 748 | $134,116.40 | 6,271 | 2026-02-02 | Filing | |
| $133.55 | 517 | $69,045.35 | 5,772 | 2025-09-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 656,465 | $148,282,315 | 0.18% | |
| 2. | 581,774 | $131,411,111 | 1.15% | |
| 3. | 336,692 | $76,051,989 | 0.04% | |
| 4. | 322,494 | $72,844,943 | 0.06% | |
| 5. | 132,210 | $29,863,595 | 1.19% |
News See All
AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?
AI startup BioinvestGPT predicted the failure of Novartis AG’s ($NVS) experimental muscular dystrophy drug months before a disappointing Phase 3 re...
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside?
Wolfe Research upgraded two prominent pharmaceutical companies to Outperform on August 13. The firm upgraded both Biogen Inc. (NASDAQ:BIIB) and AbbVie Inc.
Biogen's (BIIB) Immunology Bet Meets A Pricier Balance Sheet
On August 6, Biogen (NASDAQ:BIIB) completed its acquisition of RayThera, a privately held biotech developing small-molecule immunology therapies whose lead program entered Phase 1 trials in July 2026.
Blowing Past the Street: 46 Stocks That Crushed Q2 EPS Projections
More than 250 companies announced their earnings performance in the second quarter of the year on Wednesday, July 29, offering a fresh look at how they performed relative to what the market expected of...
10 Most Undervalued NASDAQ Stocks to Buy Right Now
In this article, we will discuss the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On July 1, Palantir CEO Alex Karp joined CNBC's 'Squawk Box' to discuss Palantir's deal with NVIDIA.
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen
In this article, we will discuss: 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen.
Biogen Inc. (NASDAQ:BIIB) Q1 2026 Earnings Call Transcript
Biogen Inc. (NASDAQ:BIIB) Q1 2026 Earnings Call Transcript April 29, 2026Biogen Inc. beats earnings expectations. Reported EPS is $3.57, expectations were $3.05. Operator: Good morning.
Biogen Inc. (BIIB) Gets Upgraded by UBS on Upcoming Pipeline Catalysts
Biogen Inc. (NASDAQ:BIIB) is one of the best stem cell therapy stocks to buy. On April 22, Biogen Inc.
8 Best Stem Cell Therapy Stocks to Buy
In this article, we will look at the 8 Best Stem Cell Therapy Stocks to Buy.
Hedge Fund Resource Center